CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis

Journal of Clinical Investigation

Volumn 112, Issue 9, 2003, Pages 1332-1341

  Liu, Zhongyu ^a   Xu, Xin ^a   Hsu, Hui Chen ^a   Tousson, Albert ^b   Yang, Ping Ar ^a   Wu, Qi ^a   Liu, Cunren ^a   Yu, Shaohua ^a   Zhang, Huang Ge ^a,c   Mountz, John D ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 2; DOXYCYCLINE; FAS LIGAND; FREUND ADJUVANT; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTHRITIS; ARTICLE; COLLAGEN TYPE 2 INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA RESPONSIVE ELEMENT; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TETRACYCLINE RESPONSIVE ELEMENT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; COLLAGEN TYPE II; DENDRITIC CELLS; DOXORUBICIN; FEMALE; GENE THERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; SPLEEN; T-LYMPHOCYTES; TISSUE THERAPY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0346969979     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200319209     Document Type: Article

References (62)

1. Holmdahl, R., et al. 1989. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS. 97:575-584.
2. Myers, L.K., Rosloniec, E.F., Cremer, M.A., and Kang, A.H. 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:1861-1878.
3. Trucco, M., Robbins, P.D., Thomson, A.W., and Giannoukakis, N. 2002. Gene therapy strategies to prevent autoimmune disorders. Curr. Gene Ther. 2:341-354.
4. Robbins, P.D., Evans, C.H., and Chernajovsky, Y. 2003. Gene therapy for arthritis. Gene Ther. 10:902-911.
5. David, C.S. 1990. Genes for MHC, TCR and MIs determine susceptibility to collagen induced arthritis. APMIS. 98:575-584.
6. Holmdahl, R., et al. 1992. Homologous collagen-induced arthritis in rats and mice are associated with structurally different major histocompatibility complex DQ-like molecules. Eur. J. Immunol. 22:419-424.
7. Taneja, V., and David, C.S. 2000. Association of MHC and rheumatoid arthritis. Regulatory role of HLA class II molecules in animal models of RA: studies on transgenic/knockout mice. Arthritis Res. 2:205-207.
8. Holmdahl, R., Bockermann, R., Backlund, J., and Yamada, H. 2002. The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Res. Rev. 1:135-147.
9. Backlund, J., et al. 2002. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur. J. Immunol. 32:3776-3784.
10. Banda, N.K., et al. 2002. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 46:3065-3075.
11. Kafienah, W., Al-Fayez, F., Hollander, A.P., and Barker, M.D. 2003. Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach. Arthritis Rheum. 48:709-718.
12. Arai, K., et al. 1996. Extrathymic differentiation of resident T cells in the joints of mice with collagen-induced arthritis. J. Immunol. 157:5170-5177.
13. Corthay, A., Backlund, J., and Holmdahl, R. 2001. Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann. Med. 33:456-465.
14. Nakajima, A., et al. 2001. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J. Clin. Invest. 107:1293-1301.
15. Tanaka, Y. 2001. The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. Drugs Today (Barc.). 37:477-484.
16. Zhang, H.G., et al. 2002. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J. Immunol. 168:4164-4172.
17. Firestein G.S. 2003. Evolving concepts of rheumatoid arthritis. Nature. 423:356-361.
18. Quayle, A.J., et al. 1993. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand. J. Immunol. 38:75-82.
19. Aarvak, T., Chabaud, M., Thoen, J., Miossec, P., and Natvig, J.B. 2000. Changes in the Th1 or Th2 cytokine dominance in the synovium of rheumatoid arthritis (RA): a kinetic study of the Th subsets in one unusual RA patient. Rheumatology (Oxford). 39:513-522.
20. Joosten, L.A., et al. 2003. Association of interleukin-18 expression with enhanced levels ofborh interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 43:339-347.
21. Iwakura, Y. 2002. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 13:341-355.
22. Eming, R., et al. 2002. Humanized mice as a model for rheumatoid arthritis. Arthritis Res. 3(Suppl.):S133-S140.
23. Tarner, I.H., et al. 2002. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol. 105:304-314.
24. Kadowaki, K.M., Matsuno, H., Tsuji, H., and Tunru, I. 1994. CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficienct mice. Clin. Exp Immunol. 97:212-218.
25. Chu, C.Q., and Londei, M. 1996. Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J. Immunol. 157:2685-2689.
26. Mageed, R.A., Adams, G., Woodrow, D., Podhajcer, O.L., and Chernajovsky, Y. 1998. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor. Gene Ther. 5:1584-1592.
27. Mountz, J.D., Hsu, H.C., Matsuki, Y., and Zhang, H.G. 2001. Apoptosis and rheumatoid arthritis: past, present, and future directions. Curr. Rheumatol. Rep. 3:70-78.
28. Van Laar, J.M., and Tyndall, A. 2003. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control. 10:57-65.
29. Zhang, H.G., et al. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162:1423-1430.
30. Zhang, H.G., et al. 2000. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum. 43:1094-1105.
31. Hsu, H.C., et al. 2001. Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum. 44:2146-2159.
32. Baetu, T.M., and Hiscott, J. 2002. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 13:199-207.
33. LeBlanc, H.N., and Ashkenazi, A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66-75.
34. MacFarlane, M. 2003. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 139:89-97.
35. Strater, J., et al. 2002. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 8:3734-3740.
36. Zauli, G., et al. 2003. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ. Res. 92:732-740.
37. Lamhamedi-Cherradi, S.E., Zheng, S.J., Maguschak, K.A., Peschon, J., and Chen, Y.H. 2003. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 4:255-260.
38. Song, K., et al. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:1095-1104.
39. Yao, Q., et al. 2003. Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther. 10:1055-1060.
40. Zhang, H.G., et al. 2000. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum. Gene Ther. 11:2431-2442.
41. Mounrz, J.D., and Zhang, H.G. 2001. Regulation of apoptosis of synovial fibroblasts. Curr. Dir. Autoimmun. 3:216-239.
42. He, T.C., et al. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95:2509-2514.
43. Harding, T.C., Geddes, B.J., Murphy, D., Knight, D., and Uney, J.B. 1998. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat. Biotechnol. 16:553-555.
44. Hoves, S., et al. 2003. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J. Immunol. 170:5406-5413.
45. Gossen, M., and Bujard, H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89:5547-5551.
46. Gossen, M., et al. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science. 268:1766-1769.
47. Baron, U., and Bujard, H. 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 327:401-421.
48. Bohl, D., Salvetti, A., Moullier, P., and Heard, J.M. 1998. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood. 92:1512-1517.
49. Kim, S.H., Kim, S., Oligino, T.J., and Robbins, P.D. 2002. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol. Ther. 6:584-590.
50. Wang, D., Hill, J.A., Jevnikar, A.M., Cairns, E., and Bell, D.A. 2002. Induction of transient arthritis by the adoptive transfer of a collagen II specific Th1 clone to HLA-DR4 (B1*0401) transgenic mice. J. Autoimmun. 19:37-43.
51. Shin, S.S., et al. 2003. Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford). 42:665-672.
52. Myers, L.K., et al. 2002. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum. 46:3369-3377.
53. Krco, C.J., et al. 1999. Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. J. Immunol. 163:1661-1665.
54. Ashany, D., Savir, A., Bhardwaj, N., and Elkon, K.B. 1999. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 163:5303-5311
55. Zhou, T., Mountz, J.D., and Kimberly, R.P. 2002. Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res. 26:323-336.
56. Zhang, H.G., et al. 2002. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J. Virol. 76:5692-5700.
57. Gardnerova, M., Blanque, R., and Gardner, C.R. 2000. The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents. Curr. Drug Targets. 1:327-364.
58. Ichikawa, K., et al. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:954-960.
59. Matsumura, R., et al. 2002. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin. Exp. Rheumatol. 20:791-798.
60. Leung, B.P., et al. 2002. A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J. Immunol. 169:7071-7077.
61. Chu, C.Q., and Londei, M. 1999. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J. Autoimmun. 12:35-42.
62. Niizawa, A., et al. 2003. Clinical and immunomodulatory effects of funboi, an herbal medicine, on collagen-induced arthritis in vivo. Clin. Exp. Rheumatol. 21:57-62.